EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Talha Munir, David A Cairns, Adrian Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankara Paneesha, Christopher P Fox, Toby A Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy und 21 weitere

New England Journal of Medicine · 25.01.2024 · 390 (4) · 326-337

DOI: 10.1056/nejmoa2310063 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 25.01.2024. Verfasst von Talha Munir und 32 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Clinical Hematology (T.M., P.H.) and the Hematological Malignancy Diagnostic Service (N.W., S.D., R.T., A.R.), Leeds Cancer Ce…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Vidarabine. Die Arbeit wurde bisher 179-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Cancer Research UK, Janssen Pharmaceutica NV, AbbVie Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Lymphocytic, Chronic, B-CellNeoplasm, ResidualVidarabineHumansBridged Bicyclo Compounds, HeterocyclicCyclophosphamideRituximabSulfonamidesTime FactorsDuration of Therapy

Substanzen

Bridged Bicyclo Compounds, HeterocyclicCyclophosphamidefludarabineRituximabSulfonamidesvenetoclaxVidarabine

Autor:innen und Institutionen

  • From the Department of Clinical Hematology (T.M., P.H.) and the Hematological Malignancy Diagnostic Service (N.W., S.D., R.T., A.R.), Leeds Cancer Centre, and the Leeds Cancer Research UK Clinical Trials Unit (D.A.C., D…

ORCID-Profile: Lelia Duley

Förderung

  • Cancer Research UK
  • Janssen Pharmaceutica NV
  • AbbVie Ltd.

Zitieren

APA

Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., …, & National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/nejmoa2310063

Vancouver

Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. 2024;390(4):326-337. doi:10.1056/nejmoa2310063

BibTeX
@article{Munir2024,
  author = {Munir, Talha and Cairns, David A and Bloor, Adrian and Allsup, David and Cwynarski, Kate and Pettitt, Andrew and Paneesha, Shankara and Fox, Christopher P and Eyre, Toby A and Forconi, Francesco and Elmusharaf, Nagah and Kennedy, Ben and Gribben, John and Pemberton, Nicholas and Sheehy, Oonagh and Preston, Gavin and Schuh, Anna and Walewska, Renata and Duley, Lelia and Howard, Dena and Hockaday, Anna and Jackson, Sharon and Greatorex, Natasha and Girvan, Sean and Bell, Sue and Brown, Julia M and Webster, Nichola and Dalal, Surita and de Tute, Ruth and Rawstron, Andrew and Patten, Piers E M and Hillmen, Peter and National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup, National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup},
  title = {Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {4},
  pages = {326--337},
  doi = {10.1056/nejmoa2310063}
}
Kostenlos starten →